Celcuity Inc. (CELC): Long-Term Debt

Annual figures by period end, from SEC filings.

$137.55M
As of 2025-12-31
$0
As of 2026-06-30
+56.7%
3-year compound annual growth
2021-12-31: $15.98M2022-12-31: $35.76M2023-12-31: $37.57M2024-12-31: $105.09M2025-12-31: $137.55M$137.55M
2021-12-31 Long-Term Debt (USD) 2025-12-31
Period endedLong-Term DebtChange YoYSource filing
2025-12-31$137.55M+30.9%2026-03-26, Balance as of period end
2024-12-31$105.09M+179.8%2025-03-31, Balance as of period end
2023-12-31$37.57M+5.1%2024-03-27, Balance as of period end
2022-12-31$35.76M+123.8%2023-03-23, Balance as of period end
2021-12-31$15.98Mn/a2022-03-23, Balance as of period end

Long-Term Debt at similar companies

Companies with the same SEC industry code (Services-Medical Laboratories), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedLong-Term DebtChange YoY
Celcuity Inc. (CELC)2025-12-31$137.55M+30.9%
Castle Biosciences Inc (CSTL)2025-12-31$10.06M+0.3%
BillionToOne, Inc. (BLLN)2025-12-31$57.23M+11.2%
Caris Life Sciences, Inc. (CAI)2025-12-31$378.45M+1.4%
Guardant Health, Inc. (GH)2025-12-31$1.50B+31.6%
Biodesix Inc (BDSX)2025-12-31$50.01M+24.9%
Exagen Inc. (XGN)2025-12-31$22.91M+13.1%
RadNet, Inc. (RDNT)2025-12-31$1.09B+7.2%
American Shared Hospital Services (AMS)2025-12-31$17.40M-14.8%

Compare CELC, CSTL, BLLN, CAI side by side · Screen every company in Services-Medical Laboratories ↗